Afatinib induces the activation of the PERK-eIF2α pathway downstream of ER stress in the head and neck squamous cell carcinoma and sorafenib induces both PERK and IRE1α activation in leukemia and hepatocellular carcinoma cells [52–54]. Here, EIF2A is linked to hepatocellular carcinoma.